Recent advances, approaches and challenges in targeting pathways for potential COVID-19 vaccines development

被引：0

作者：

Daniela Calina

Chandan Sarkar

Andreea Letitia Arsene

Bahare Salehi

Anca Oana Docea

Milon Mondal

Muhammad Torequl Islam

Alireza Zali

Javad Sharifi-Rad

机构：

[1] University of Medicine and Pharmacy of Craiova,Department of Clinical Pharmacy

[2] Bangabandhu Sheikh Mujibur Rahman Science and Technology University,Department of Pharmacy

[3] Carol Davila University of Medicine and Pharmacy,Department of Department of Microbiology

[4] Bam University of Medical Sciences,Noncommunicable Diseases Research Center

[5] Bam University of Medical Sciences,Student Research Committee, School of Medicine

[6] University of Medicine and Pharmacy of Craiova,Department of Toxicology

[7] Shahid Beheshti University of Medical Sciences,Functional Neurosurgery Research Center, Shohada Tajrish Neurosurgical Comprehensive Center of Excellence

[8] Shahid Beheshti University of Medical Sciences,Phytochemistry Research Center

来源：

Immunologic Research | 2020年 / 68卷

关键词：

SARS-CoV-2; COVID-19 pandemic ; Immunology ; Candidate vaccines; Safety ; Efficacy ; Quality ; Public health;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

During the COVID-19 pandemic in a modern era, there is a global consensus on the need for the rapid development of a vaccine against SARS-CoV-2 for effective and sustainable control. Developing these vaccines is fundamental to public health. This urgent need is supported by the scientific explosion in structural and genomic biology that facilitates the urgent development of an ideal COVID-19 vaccine, using new pathways to facilitate its large-scale development, testing, and manufacture. Here, we summarize the types of COVID-19 candidate vaccines, their current stage in early testing in human clinical trials, and the challenges for their implementation.

引用

页码：315 / 324

页数：9

共 335 条

[1]

Docea AO(2020)A new threat from an old enemy: re-emergence of coronavirus Int J Mol Med 45 1631-1643

[2]

Tsatsakis A(2020)Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study Lancet 395 507-513

[3]

Albulescu D(2020)COVID-19 in Northern Italy: an integrative overview of factors possibly influencing the sharp increase of the outbreak Mol Med Rep 22 20-32

[4]

Cristea O(2020)COVID-19, an opportunity to reevaluate the correlation between long-term effects of anthropogenic pollutants on viral epidemic/pandemic events and prevalence Food Chem Toxicol 141 111418-1066

[5]

Zlatian O(2004)Chronological evolution of IgM, IgA, IgG and neutralisation antibodies after infection with SARS-associated coronavirus Clin Microbiol Infect 10 1062-119

[6]

Vinceti M(2020)Evaluation of the EUROIMMUN anti-SARS-CoV-2 ELISA assay for detection of IgA and IgG antibodies J Clin Virol 129 104468-6

[7]

Moschos SA(2020)Multiplex detection and dynamics of IgG antibodies to SARS-CoV2 and the highly pathogenic human coronaviruses SARS-CoV and MERS-CoV J Clin Virol 129 104521-465

[8]

Tsoukalas D(2020)Human neutralizing antibodies elicited by SARS-CoV-2 infection Nature 584 115-1973

[9]

Goumenou M(2020)A human monoclonal antibody blocking SARS-CoV-2 infection Nat Commun 11 1-73

[10]

Drakoulis N(2020)Improving vaccine-induced immunity: can Baseline Predict Outcome? Trends Immunol 41 457-16

← 1 2 3 4 5 6 7 8 9 10 →